Drug Use Clinical Trial
Official title:
Gender-Responsive Drug Use Treatment for Juvenile Justice Girls
Verified date | December 2020 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Girls in the juvenile justice system have unique developmental pathways to drug use and co-occurring risk (e.g., HIV/STI) behaviors that have typically not been considered or tested in order to identify evidence-based gender-specific substance use treatment approaches for this population. This study will advance scientific knowledge and clinical practice in the drug treatment and public health fields by testing the efficacy of a pre-existing, widely disseminated gender-responsive substance use treatment (VOICES) on drug use and HIV/STI risk behavior outcomes for a broad range of substance using girls and young women (ages 12-24) who are at-risk for or already involved with the justice system.
Status | Completed |
Enrollment | 132 |
Est. completion date | September 2020 |
Est. primary completion date | September 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 12 Years to 24 Years |
Eligibility | Inclusion Criteria: 130 court-involved, non-incarcerated (CINI) female juvenile offenders or those at-risk for court-involvement, ages 12-24, who report any alcohol, marijuana or other drug use in the past 90 days will be eligible for enrollment with the following criteria: 1) Determined to be in need of substance use treatment by the court intake worker, probation officer, presiding judge or magistrate, and/or school counselor; 2) Legal guardian available to consent for child's participation, if the child is under the age of 18, and 3) Child is English speaking. Exclusion Criteria: 1. meet DSM-V criteria for substance use disorder with current severity rating of severe (6 or more symptoms) (as determined through referral partner); 2. already in substance use treatment (residential or outpatient) and wish to remain with outside provider (as determined through referral partner); 3. observable cognitive or developmental delays or active psychosis that would interfere with completing consent, assessment or intervention. |
Country | Name | City | State |
---|---|---|---|
United States | UCSF Zuckerberg San Francisco General Hospital | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Marijuana Use | self-reported frequency (e.g., number of days used) as measured by the Adolescent Risk Behavior Assessment (ARBA) | baseline, 1-month post-baseline (mid-treatment), 3 months post-baseline (end of treatment), and -3 and -6 month post-treatment completion to assess change over time | |
Primary | Alcohol Use | self-reported quantity and frequency (e.g., number of days used, number of drinks consumed each day) as measured by the Adolescent Risk Behavior Assessment (ARBA) | baseline, 1-month post-baseline (mid-treatment), 3 months post-baseline (end of treatment), and -3 and -6 month post-treatment completion to assess change over time | |
Primary | Other Drug Use | self-reported quantity and frequency (e.g., number of days and types of other drugs used) as measured by the Adolescent Risk Behavior Assessment (ARBA) | baseline, 1-month post-baseline (mid-treatment), 3 months post-baseline (end of treatment), and -3 and -6 month post-treatment completion to assess change over time | |
Primary | Drug Urinalysis Screen | Collateral measure of recent substance use (10-panel screen for Methadone, Amphetamine, Opiate, Oxycodone, Benzodiazepines, Barbiturates, Methamphetamine, Cocaine, Marijuana and Propoxyphene) | baseline, 3 months post-baseline (end of treatment), and -3 and -6 month post-treatment completion to assess change over time | |
Primary | HIV/STI risk behavior | self-reported frequency of sexual activity, condom use at last sex and substance use during sexual activity measured by the Adolescent Risk Behavior Assessment (ARBA) | baseline, 1-month post-baseline (mid-treatment), 3 months post-baseline (end of treatment), and -3 and -6 month post-treatment completion to assess change over time | |
Secondary | Psychiatric Symptoms | Brief Symptom Inventory (self-report psychiatric symptom questionnaire) | baseline, 1-month post-baseline (mid-treatment), 3 months post-baseline (end of treatment), and -3 and -6 month post-treatment completion to assess change over time | |
Secondary | Traumatic Stress | National Stressful Events Survey PTSD Short Scale (NSESSS; self-report of posttraumatic stress symptoms and severity) | baseline, 1-month post-baseline (mid-treatment), 3 months post-baseline (end of treatment), and -3 and -6 month post-treatment completion to assess change over time | |
Secondary | Recidivism | Collateral/legal chart data to measure whether youth accrues any new/additional legal charges, is arrested and/or detained | baseline to 6-months post-treatment completion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05468879 -
Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects
|
N/A | |
Not yet recruiting |
NCT06395129 -
Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
|
||
Completed |
NCT01941108 -
Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care
|
N/A | |
Completed |
NCT01380613 -
Neighborhoods, Networks, Depression, and HIV Risk
|
Phase 2 | |
Withdrawn |
NCT00914719 -
Alcohol Use and Sexual Risk: An Intervention
|
N/A | |
Recruiting |
NCT03671629 -
Pharmacist Intervention to Reduce Drug-related Readmissions Among the Elderly
|
N/A | |
Completed |
NCT03290391 -
Linking Infectious and Narcology Care-Part II
|
Phase 4 | |
Completed |
NCT04008927 -
A Community-based Intervention Among Active Drug Users in Montpellier
|
N/A | |
Completed |
NCT03627546 -
HCV Seek, Test and Rapid Treatment for Young PWID
|
N/A | |
Not yet recruiting |
NCT03967262 -
Secondary Prevention and Recidivism Reduction in Trauma Patients
|
N/A | |
Completed |
NCT03079856 -
Drug Use and Sexual Risk Behaviors Among Emerging Adults in the ER
|
N/A | |
Completed |
NCT03855410 -
Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention
|
N/A | |
Terminated |
NCT02457949 -
The Impact of Alternative Social Assistance Disbursement on Drug-related Harm
|
N/A | |
Completed |
NCT06238154 -
Flurbiprofen Tablet vs Spray In Oral Soft Tissue Wounds
|
Phase 4 | |
Terminated |
NCT04436055 -
Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
|
||
Recruiting |
NCT04717856 -
Evaluation of the Use of the GenXpert to Detect Hepatitis C RNA
|
N/A | |
Completed |
NCT00249496 -
Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1
|
N/A | |
Recruiting |
NCT05597865 -
Assessing the Feasibility of Economic Approaches to Prevent Substance Abuse Among Adolescents
|
N/A | |
Completed |
NCT05553054 -
Drug Wastage : Observational Study in Intensive Care Units in France
|
||
Completed |
NCT03718520 -
The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
|